Denali Therapeutics (DNLI)
NASDAQ:DNLI
Top Page
Denali Therapeutics
(NASDAQ:DNLI)
Select Model
Select Model
Rating:51Neutral
Price Target:
$18.00
▼(-8.26% Downside)
Action:ReiteratedDate:04/01/26
The score is held back primarily by weak financial performance (widening losses, cash burn, and recent $0 revenue) and bearish technical signals. These are partly offset by strong, positive corporate catalysts (FDA accelerated approval and $200M non-dilutive funding) and a low-leverage balance sheet.
Positive Factors
TransportVehicle BBB platform
Denali's TransportVehicle tech enabled the FDA's accelerated approval of a brain-penetrant biologic, giving it a structural delivery advantage for CNS drugs. A platform that reliably crosses the blood-brain barrier can expand addressable indications, de-risk multiple programs, and sustain competitive differentiation across years.
Negative Factors
Sustained cash burn
Operating and free cash flows have been persistently negative, indicating ongoing burn to fund development. Continued multi-hundred-million annual outflows increase dependency on financing or milestone receipts and constrain ability to scale commercial operations if product revenues are delayed or lower than expected.
Read all positive and negative factors
Positive Factors
Negative Factors
TransportVehicle BBB platform
Denali's TransportVehicle tech enabled the FDA's accelerated approval of a brain-penetrant biologic, giving it a structural delivery advantage for CNS drugs. A platform that reliably crosses the blood-brain barrier can expand addressable indications, de-risk multiple programs, and sustain competitive differentiation across years.
Read all positive factors
Denali Therapeutics (DNLI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.11B
Dividend YieldN/A
Average Volume (3M)1.82M
Price to Earnings (P/E)―
Beta (1Y)2.01
Revenue GrowthN/A
EPS Growth-5.30%
CountryUS
Employees443
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.73
Shares Outstanding158,591,490
10 Day Avg. Volume2,238,135
30 Day Avg. Volume1,815,806
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.03K
Enterprise Value/Ebitda-5.55
Forecast
1Y Price Target
$36.27Price Target Upside84.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.58
Revenue Forecast (FY)$58.31M
Denali Therapeutics Business Overview & Revenue Model
Company Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122...
How the Company Makes Money
Denali primarily generates revenue from collaboration and licensing arrangements rather than from product sales, because it is a clinical-stage company with no broadly commercialized products. Key revenue streams typically include: (1) upfront pay...
Denali Therapeutics Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 330.53M | 108.46M | 48.66M |
| Gross Profit | -11.18M | 0.00 | 330.53M | 108.46M | 48.66M |
| EBITDA | -497.63M | -492.89M | -179.97M | -330.36M | -287.16M |
| Net Income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M |
Balance Sheet | |||||
| Total Assets | 1.14B | 1.37B | 1.15B | 1.46B | 1.40B |
| Cash, Cash Equivalents and Short-Term Investments | 867.88M | 832.33M | 1.03B | 1.34B | 865.41M |
| Total Debt | 42.29M | 48.71M | 52.24M | 60.35M | 64.01M |
| Total Liabilities | 131.09M | 144.50M | 122.96M | 417.81M | 441.87M |
| Stockholders Equity | 1.01B | 1.23B | 1.03B | 1.04B | 962.29M |
Cash Flow | |||||
| Free Cash Flow | -422.10M | -363.61M | -370.93M | -262.55M | -219.89M |
| Operating Cash Flow | -412.60M | -347.69M | -357.99M | -244.72M | -211.39M |
| Investing Cash Flow | 255.28M | -88.76M | 249.31M | -141.39M | -21.63M |
| Financing Cash Flow | 189.22M | 484.30M | 17.82M | 310.67M | 19.35M |
Denali Therapeutics Technical Analysis
Neutral
19.62
Price Trends
20.46
Negative
19.18
Positive
16.99
Positive
Market Momentum
-0.25
Positive
47.77
Neutral
30.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNLI, the sentiment is Neutral. The current price of 19.62 is below the 20-day moving average (MA) of 20.13, below the 50-day MA of 20.46, and above the 200-day MA of 16.99, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 30.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DNLI.
Denali Therapeutics Risk Analysis
Denali Therapeutics disclosed 75 risk factors in its most recent earnings report. Denali Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Denali Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $2.89B | ― | -10.26% | ― | 129.21% | 80.35% | |
62 Neutral | $5.65B | -29.60 | -203.17% | ― | ― | -40.75% | |
54 Neutral | $2.59B | -34.27 | -7.31% | ― | -84.07% | -157.71% | |
52 Neutral | $1.98B | -3.82 | -31.07% | ― | 36.26% | -158.98% | |
52 Neutral | $2.72B | -26.90 | -11.10% | ― | 5376.27% | 20.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $3.11B | -5.65 | -50.13% | ― | ― | -5.30% |
* Healthcare Sector Average
DNLI
Denali Therapeutics
19.62
6.76
52.57%
AGIO
Agios Pharma
33.77
7.49
28.50%
CELC
Celcuity
116.94
108.29
1251.91%
IDYA
IDEAYA Biosciences
30.96
15.18
96.20%
ARQT
Arcutis Biotherapeutics
24.61
10.04
68.91%
BEAM
Beam Therapeutics
25.44
9.07
55.41%
Denali Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Denali Therapeutics Secures $200 Million Royalty Funding
Positive
Mar 31, 2026
Denali Therapeutics Inc. secured $200 million in gross proceeds on March 27, 2026, upon closing a synthetic royalty funding agreement with Royalty Pharma. The transaction closed shortly after the U.S. Food and Drug Administration granted accelerat...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Denali Therapeutics Gains FDA Approval for AVLAYAH Therapy
Positive
Mar 25, 2026
On March 25, 2026, Denali Therapeutics announced that the U.S. Food and Drug Administration granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy for neurologic manifestations of Hunter syndrome in presymp...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision
Positive
Jan 6, 2026
On January 6, 2026, Denali Therapeutics outlined its key priorities and expected milestones for 2026, positioning the year as a pivotal period as it prepares for a potential U.S. accelerated approval and commercial launch of tividenofusp alfa for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.